{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-24-008332","form_type":"8-K","ticker":"SNOA","cik":"0001367083","company_name":"Sonoma Pharmaceuticals, Inc.","filed_at":"2024-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.266106+00:00","generated_at":"2026-05-29T20:28:38.033478+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Sonoma Pharmaceuticals terminates exclusive supply agreement with EMC Pharma","bullets":["EMC Pharma failed to meet minimum purchase quantities; 30-day cure period expired.","Termination effective November 21, 2024; no penalties incurred by Sonoma.","Sonoma resumes direct U.S. sales of Microcyn-based products: Acuicyn, Celacyn, Epicyn, Lasercyn, Levicyn.","Agreement had a five-year initial term; exclusive distribution rights now ended."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-24-008332","json":"https://secwatch.observer/filing/0001683168-24-008332.json","markdown":"https://secwatch.observer/filing/0001683168-24-008332.md","text":"https://secwatch.observer/filing/0001683168-24-008332.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824008332/0001683168-24-008332-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367083/000168316824008332/sonoma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T20:28:38.033478+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}